KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Dynavax Technologies (DVAX) EBITDA: 2009-2024

Historic EBITDA for Dynavax Technologies (DVAX) over the last 16 years, with Dec 2024 value amounting to -$4.1 million.

  • Dynavax Technologies' EBITDA rose 110.98% to $21.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.4 million, marking a year-over-year increase of 195.06%. This contributed to the annual value of -$4.1 million for FY2024, which is 88.87% up from last year.
  • According to the latest figures from FY2024, Dynavax Technologies' EBITDA is -$4.1 million, which was up 88.87% from -$37.0 million recorded in FY2023.
  • In the past 5 years, Dynavax Technologies' EBITDA ranged from a high of $283.5 million in FY2022 and a low of -$68.4 million during FY2020.
  • Moreover, its 3-year median value for EBITDA was -$4.1 million (2024), whereas its average is $80.8 million.
  • As far as peak fluctuations go, Dynavax Technologies' EBITDA soared by 296.70% in 2021, and later plummeted by 113.06% in 2023.
  • Dynavax Technologies' EBITDA (Yearly) stood at -$68.4 million in 2020, then soared by 296.70% to $134.5 million in 2021, then spiked by 110.82% to $283.5 million in 2022, then plummeted by 113.06% to -$37.0 million in 2023, then spiked by 88.87% to -$4.1 million in 2024.